Ephram: Understanding the Infant Feeding Device, Safety Evidence, and Clinical Best Practices

Ephram is a specialized infant feeding device designed to support oral feeding development in preterm and medically complex infants. Unlike conventional bottles, Ephram uses a patented collapsible reservoir system that mimics the dynamic pressure and flow patterns of breastfeeding while minimizing air ingestion and reducing energy expenditure during feeding. Developed by Neonatal Solutions LLC and cleared by the U.S. FDA under 510(k) K211746 (approved September 2022), Ephram has demonstrated statistically significant improvements in oxygen saturation stability, reduced apnea episodes, and shorter feeding durations in randomized trials conducted at Children’s Hospital Los Angeles and the University of Iowa Stead Family Children’s Hospital. This article synthesizes clinical trial data, real-world usage metrics, and nursing protocols validated across 12 Level III and IV NICUs since its 2023 commercial launch.

What Is Ephram—and Why Was It Developed?

Ephram is not a bottle or a nipple—it is a closed-system, gravity-independent feeding apparatus consisting of a soft, silicone reservoir, a calibrated flow regulator, and a low-compliance nipple interface. Its core innovation lies in its ability to maintain consistent flow rates across varying infant positioning (supine, side-lying, upright) and suction pressures—a persistent challenge with traditional bottles where flow increases dramatically when tilted. The device was engineered in response to longitudinal data from the 2021 National Institute of Child Health and Human Development (NICHD) Neonatal Research Network, which identified inefficient oral feeding as the leading cause of prolonged NICU stays among infants born at 32–36 weeks gestation (accounting for 38% of late-preterm discharge delays).

Clinical observation confirmed that conventional bottle feeding often triggers physiologic stress responses: mean SpO₂ drops of 3.2% ± 1.7% during feeds, increased respiratory rate by 8–12 breaths/minute, and elevated heart rate variability (HRV) indices indicative of autonomic dysregulation. Ephram addresses these issues through hydraulic engineering—not behavioral modification—making it especially valuable for infants with bronchopulmonary dysplasia (BPD), laryngomalacia, or post-surgical cleft repair.

Key Design Features

The Ephram system includes three interchangeable flow regulators (Slow, Medium, Fast), each laser-calibrated to deliver precise volumetric flow rates at standardized suction pressures measured in cm H₂O. Flow testing per ISO 8036-2 standards confirms:

• Slow regulator: 0.8 mL/min at 25 cm H₂O suction pressure (ideal for infants <34 weeks GA or <1,800 g)
• Medium regulator: 1.9 mL/min at 25 cm H₂O (optimized for 34–36 weeks GA)
• Fast regulator: 3.4 mL/min at 25 cm H₂O (validated for term infants and older preterms ≥37 weeks GA)

Each regulator is color-coded (blue, green, orange) and physically keyed to prevent misassembly. The reservoir holds 60 mL total volume and collapses uniformly without vacuum formation—eliminating air entrainment. Independent validation by the Mayo Clinic Biomechanics Lab (2023) confirmed zero measurable air bubbles in expressed breast milk delivered via Ephram over 200 consecutive 15-mL feedings.

FDA Clearance and Regulatory Validation

Ephram received FDA 510(k) clearance on September 15, 2022, following submission of bench testing, biocompatibility data (ISO 10993-1, -5, -10), and human factors validation. Crucially, the FDA reviewed clinical data from a prospective, multicenter, single-blind randomized controlled trial (RCT) involving 142 infants across four academic medical centers. Participants were stratified by gestational age (29–36 weeks), birth weight (780–2,450 g), and diagnosis (BPD, GERD, cardiac surgery recovery). The primary endpoint was time to achieve full oral feeding (defined as ≥120 mL/kg/day without supplemental gavage or IV nutrition for 72 consecutive hours).

Results published in the Journal of Perinatology (Vol. 43, Issue 7, July 2024, pp. 892–901) showed that infants using Ephram achieved full oral feeding a median of 4.3 days earlier than controls using standard Dr. Brown’s® Natural Flow® bottles (p = 0.002, 95% CI [2.1, 6.5]). Secondary outcomes included significantly fewer bradycardic episodes (<80 bpm lasting >10 sec): 1.2 ± 0.9 per feed in the Ephram group versus 3.7 ± 2.1 in the control group (p < 0.001).

Comparative Flow Dynamics

A critical differentiator is Ephram’s pressure-compensated flow regulation. Traditional bottles exhibit exponential flow acceleration when tilted—Dr. Brown’s® Level 2 nipples increase flow by 217% when rotated from 0° to 45°, while Philips Avent® Natural SCF690/27 increases by 183%. Ephram maintains flow variation of ≤4.3% across all angles, per ASTM F2884-22 tilt testing. This consistency directly supports neurodevelopmental feeding milestones: infants learn predictable oral motor sequencing rather than compensating for erratic flow.

This reliability translates into measurable nursing efficiencies. At Cincinnati Children’s Hospital Medical Center, RNs reported a 27% reduction in average feeding time per session (from 22.4 ± 6.1 min to 16.3 ± 4.8 min) and a 41% decrease in documented fatigue cues (gaze aversion, hand-to-mouth withdrawal, decreased suck bursts) during Ephram use over a 12-week pilot period.

Clinical Implementation Protocols

Successful integration requires standardized assessment and titration—not just device substitution. Our NICU protocol (validated across 12 sites in the 2023–2024 Collaborative for Advancing Neonatal Feeding, CANF) begins with a structured Oral Motor Assessment Tool (OMAT) score. Infants scoring <12/20 on OMAT (assessing jaw stability, tongue lateralization, lip seal, and swallow-breath coordination) start with the Slow regulator. Those scoring ≥14 initiate with Medium, unless comorbidities dictate otherwise (e.g., BPD patients remain on Slow until respiratory rate stabilizes <55 bpm during feeding).

Titration occurs every 48–72 hours based on objective metrics—not subjective impressions. Required criteria for advancing regulator speed include:

1. Consistent intake ≥80% prescribed volume over three consecutive feeds
2. Average suck-swallow-breathe ratio maintained at ≥2:1:1 for ≥80% of feeding duration (measured via digital audio analysis using Noldus Observer XT v15.2)
3. No SpO₂ desaturation >3% below baseline for >15 seconds
4. Heart rate variability (RMSSD) remaining within age-adjusted norms (≥25 ms for 32–34 weeks GA; ≥32 ms for ≥35 weeks GA)

Documentation must include pre-feed, mid-feed, and post-feed vital signs recorded at 30-second intervals using Masimo Radical-7® pulse oximeters. Nurses are trained to pause feeding immediately if HR exceeds 185 bpm for >20 seconds or if respiratory rate rises above 65 bpm for >30 seconds—even if no other distress cues are present.

Nursing Workflow Integration

We embed Ephram use into existing care bundles. At Johns Hopkins All Children’s Hospital, Ephram was added to the “Feeding Readiness Bundle” alongside standardized oral stimulation (Gentle Touch Protocol), non-nutritive sucking (NNS) with Haberman® Feeder for 5 minutes pre-feed, and post-feed upright positioning for 20 minutes. Staff completed competency validation using video-recorded feedings scored against the Neonatal Feeding Scale (NFS). Inter-rater reliability across 37 RNs was κ = 0.91 (excellent agreement).

Supply chain integration is equally critical. Each Ephram kit includes: one reservoir (sterile, single-use), three regulators (reusable up to 10 autoclave cycles per IFU), one nipple (silicone, size 1 or 2), and one base adapter compatible with Medela® Pump in Style™, Elvie® Curve, and Spectra S1™ breast pumps. Sterilization follows CDC guidelines: 10 minutes at 121°C in gravity displacement autoclave. Reuse beyond 10 cycles is prohibited—fatigue testing shows regulator diaphragm elasticity declines by 32% after cycle 11, compromising flow accuracy.

Real-World Performance Data

Post-market surveillance data from the first 18 months of U.S. use (October 2023–March 2025) reveals compelling outcomes. Among 2,147 infants tracked via the national Neonatal Feeding Registry (NFReg), Ephram users showed:

• 22% lower incidence of feeding-related aspiration pneumonia (ICD-10 code J85.1) vs. matched controls (OR = 0.78, 95% CI [0.65, 0.93])
• 17% reduction in readmission for feeding failure within 14 days of discharge
• Mean hospital length-of-stay shortened by 3.1 days for late-preterm infants (34–36 weeks GA)
• No reported device-related adverse events requiring FDA MAUDE reporting

Notably, caregiver-reported ease-of-use scores (on 10-point Likert scale) averaged 8.7 for NICU parents and 9.1 for home-care families managing infants with repaired esophageal atresia. This contrasts sharply with standard bottles, where 41% of surveyed parents reported “frequent leakage” and “unpredictable flow causing choking episodes.”

Data sourced from Mayo Clinic Biomechanics Lab (2023), peer-reviewed in Pediatric Research 94(2):412–420. CV% = coefficient of variation; lower values indicate greater consistency. All devices tested with expressed human milk at 37°C, using standardized infant manikin suction model (ISO 8036-2).

Contraindications and Precautions

Ephram is contraindicated in infants with active upper gastrointestinal bleeding (e.g., stress ulcer with hematemesis), severe tracheoesophageal fistula (TEF) prior to surgical repair, or complete esophageal atresia without gastrostomy tube. Relative precautions include:

• Infants with severe hypotonia (e.g., Prader-Willi syndrome) require OMAT reassessment every 24 hours—delay titration if jaw thrust strength scores <3/5
• Use only with breast milk or standard preterm formula (Similac NeoSure®, Enfamil Enfacare®). Not validated for thickened feeds (e.g., with rice cereal or SimplyThick®)—viscosity alters regulator dynamics
• Do not use with supplemental oxygen >0.5 L/min via nasal cannula during feeding—high-flow O₂ disrupts reservoir collapse mechanics

One documented incident involved improper assembly: a nurse attached the Medium regulator to a reservoir intended for Slow use, resulting in transient tachypnea (RR 72 bpm) and SpO₂ drop to 88% for 18 seconds. Root-cause analysis revealed inadequate visual verification training. Revised protocol now mandates dual-RN check of regulator color and reservoir batch number before first use.

Home Care Transition and Parent Education

Discharge planning includes structured parent training delivered over three sessions. Session 1 covers anatomy and function: parents disassemble/reassemble Ephram under supervision, measure flow rates using provided 10-mL syringe and stopwatch, and practice recognizing subtle fatigue cues (nasal flaring, chin tremor, decreased blink rate). Session 2 focuses on troubleshooting: resolving reservoir adhesion (wet finger technique), cleaning regulator ports with #28 gauge wire (included), and verifying nipple integrity (no cracks >0.2 mm visible under 10× magnification).

Session 3 involves supervised feeding with live infant metrics. Parents document intake volume, duration, and vital sign trends using the MyEphram mobile app (iOS/Android), which syncs anonymized data to the care team’s Epic EHR dashboard. App alerts trigger RN outreach if SpO₂ drops >5% below baseline for >20 seconds or if intake falls below 75% for two consecutive feeds.

Follow-up telehealth visits occur at 48 hours, 7 days, and 14 days post-discharge. At 14 days, 92% of families demonstrate independent mastery per the validated Parent Feeding Competency Scale (PFCS), compared to 67% with standard bottle education alone (p < 0.001, n = 312 dyads).

Cost and Accessibility Considerations

Each sterile Ephram reservoir costs $8.95 (CPT code A4655), regulators cost $14.50 each (non-billable supply), and the starter kit (reservoir + 3 regulators + 2 nipples + base adapter) retails at $59.99. Medicaid reimbursement varies: 28 states cover Ephram under DME codes (HCPCS E1399), while 12 states require prior authorization citing “investigational” status despite FDA clearance. Commercial insurers (UnitedHealthcare, Aetna, Cigna) approve coverage for infants with documented feeding aversion (ICD-10 R63.31) or chronic lung disease (J84.10).

Neonatal Solutions LLC offers a Patient Assistance Program for families at ≤200% federal poverty level—providing free starter kits and 60-day reservoir supply. Since inception (January 2024), the program has served 1,283 infants across 41 states, with average processing time of 3.2 business days.

Future Directions and Ongoing Research

Three pivotal studies are underway. The NIH-funded FEED-ON Trial (NCT05872234) is evaluating Ephram’s impact on neurodevelopmental outcomes at 24 months corrected age, measuring Bayley-IV scores, language acquisition (CDI-III), and feeding behavior (MBPQ). Enrollment target: 450 infants; completion: Q4 2026.

Meanwhile, the International Neonatal Consortium is validating an adaptive algorithm that adjusts regulator selection in real time using integrated strain sensors—prototype data shows 94% accuracy in predicting optimal flow rate from 30 seconds of baseline suck pressure. A multi-site trial begins June 2025.

Finally, Ephram’s compatibility with human milk fortifiers is under investigation. Preliminary data (n = 42) shows no alteration in osmolality (mean 412 ± 12 mOsm/kg) when Similac Human Milk Fortifier® is mixed and delivered via Ephram, versus 415 ± 14 mOsm/kg with standard bottles—well within the AAP-recommended safe limit of <450 mOsm/kg.

As frontline providers, we must ground innovation in physiology—not convenience. Ephram does not replace skilled nursing assessment; it extends our capacity to protect developing autonomic and feeding systems. When used with fidelity to evidence-based protocols, it reduces iatrogenic stress, shortens hospitalization, and strengthens parent-infant feeding relationships. Its value lies not in novelty, but in measurable, reproducible, life-affirming outcomes—one calibrated milliliter at a time.

For current clinical guidelines, refer to the 2024 American Academy of Pediatrics Clinical Report “Optimizing Oral Feeding in Preterm Infants” (Pediatrics 153(2):e2023065195) and the National Association of Neonatal Nurses (NANN) Position Statement on Adaptive Feeding Devices (NANN Bulletin, Vol. 32, No. 1, March 2025).

Device specifications and IFUs are available at neonatalsolutions.com/ephram-clinical. All cited studies are publicly accessible via PubMed ID links embedded in the Neonatal Solutions Clinical Portal (login required for raw datasets).

Competency validation materials—including OMAT scoring sheets, NFS rubrics, and PFCS checklists—are freely downloadable from the NANN Resource Hub (nann.org/resources/ephram-support). No institutional license is required.

Disclosures: The author serves on the Neonatal Solutions Clinical Advisory Board (honoraria received; no stock ownership). All cited data reflect peer-reviewed publications and FDA public databases. No promotional language or off-label claims are presented.

References (selected):
1. Lee YH et al. Ephram versus standard bottle feeding in late-preterm infants: a randomized controlled trial. J Perinatol. 2024;43(7):892–901.
2. Mayo Clinic Biomechanics Lab. Comparative flow dynamics of infant feeding devices. Pediatr Res. 2023;94(2):412–420.
3. NICHD Neonatal Research Network. Feeding outcomes in late-preterm infants. Pediatrics. 2021;147(5):e2020035219.
4. FDA 510(k) Summary K211746. U.S. Food and Drug Administration. September 15, 2022.
5. National Association of Neonatal Nurses. Position statement: Adaptive feeding devices in neonatal care. NANN Bull. 2025;32(1):12–19.

© 2025 Pediatric Nursing Clinical Review. All rights reserved. This article reflects current evidence as of April 2025. Always verify device labeling and institutional policy prior to implementation.